Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference
December 18 2023 - 8:00AM
Esperion (NASDAQ: ESPR) today announced its participation in the
42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig,
President and CEO, will deliver a corporate presentation on
Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The
Esperion management team will also be hosting investor meetings
during the conference.
To register for the live webcast, follow this
link.
A live audio webcast can be accessed on the investor and media
section of the Esperion website. Access to the webcast replay will
be available approximately two hours after completion of the call
and will be archived on the Company's website for approximately 90
days.
Esperion TherapeuticsAt Esperion, we discover,
develop, and commercialize innovative medicines to help improve
outcomes for patients with or at risk for cardiovascular and
cardiometabolic diseases. The status quo is not meeting the health
needs of millions of people with high cholesterol – that is why our
team of passionate industry leaders is breaking through the
barriers that prevent patients from reaching their goals. Providers
are moving toward reducing LDL-cholesterol levels as low as
possible, as soon as possible; we provide the next steps to help
get patients there. Because when it comes to high cholesterol,
getting to goal is not optional. It is our life’s work. For more
information, visit esperion.com and esperionscience.com and follow
us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information: Investors:
Alexis Callahaninvestorrelations@esperion.com(406)
539-1762 Media: Tiffany Aldrich
corporateteam@esperion.com(616) 443-8438
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Sep 2023 to Sep 2024